Relmada Therapeutics RLMD Stock
4.65 USD
{{ price }}
-0.214587%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqGS
Market Cap
140.31M USD
LOW - HIGH [24H]
4.54
-
4.68 USD
VOLUME [24H]
120.02K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-3.28 USD
Relmada Therapeutics Price Chart
Relmada Therapeutics RLMD Financial and Trading Overview
| Relmada Therapeutics stock price | 4.65 USD |
| Previous Close | 2.57 USD |
| Open | 2.57 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 2.47 - 2.57 USD |
| 52 Week Range | 1.81 - 38.68 USD |
| Volume | 136.91K USD |
| Avg. Volume | 174.45K USD |
| Market Cap | 76.75M USD |
| Beta (5Y Monthly) | 0.165845 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.28 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.63 USD |
RLMD Valuation Measures
| Enterprise Value | -55087044 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.9922179 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.61165744 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Relmada Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.165845 |
| 52-Week Change | -86.065% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 38.68 USD |
| 52 Week Low | 1.81 USD |
| 50-Day Moving Average | 2.82 USD |
| 200-Day Moving Average | 8.26 USD |
RLMD Share Statistics
| Avg. Volume (3 month) | 174.45K USD |
| Avg. Daily Volume (10-Days) | 123.59K USD |
| Shares Outstanding | 30.1M |
| Float | 22.54M |
| Short Ratio | 13.68 |
| % Held by Insiders | 7.78% |
| % Held by Institutions | 66.22% |
| Shares Short | 2.08M |
| Short % of Float | 7.04% |
| Short % of Shares Outstanding | 6.91% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -52.26% |
| Return on Equity (ttm) | -85.52% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -143619616 USD |
| Diluted EPS (ttm) | -4.71 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 132.44M USD |
| Total Cash Per Share (mrq) | 4.4 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 13.423 |
| Book Value Per Share (mrq) | 4.169 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -100876968 USD |
| Levered Free Cash Flow (ttm) | -54094576 USD |
Profile of Relmada Therapeutics
| Country | United States |
| State | FL |
| City | Coral Gables |
| Address | 2222 Ponce de Leon Boulevard |
| ZIP | 33134 |
| Phone | 786 629 1376 |
| Website | https://www.relmada.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 14 |
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Q&A For Relmada Therapeutics Stock
What is a current RLMD stock price?
Relmada Therapeutics RLMD stock price today per share is 4.65 USD.
How to purchase Relmada Therapeutics stock?
You can buy RLMD shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Relmada Therapeutics?
The stock symbol or ticker of Relmada Therapeutics is RLMD.
Which industry does the Relmada Therapeutics company belong to?
The Relmada Therapeutics industry is Biotechnology.
How many shares does Relmada Therapeutics have in circulation?
The max supply of Relmada Therapeutics shares is 30.17M.
What is Relmada Therapeutics Price to Earnings Ratio (PE Ratio)?
Relmada Therapeutics PE Ratio is now.
What was Relmada Therapeutics earnings per share over the trailing 12 months (TTM)?
Relmada Therapeutics EPS is -3.28 USD over the trailing 12 months.
Which sector does the Relmada Therapeutics company belong to?
The Relmada Therapeutics sector is Healthcare.
Relmada Therapeutics RLMD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}